VitaSynth

What VitaSynth does

VitaSynth sp. z o.o. is a privately held Polish manufacturer of pharmaceutical-grade vitamin K2 MK-7, founded in 2009 and headquartered in Koprki near Warsaw. The company operates its own European manufacturing site, producing the Pharmaquinone® line of ingredients under a proprietary, patented second-generation synthesis and purification process that yields the only commercially available "single-peak" vitamin K2 — a formulation that does not contain the cis isomer per the US Pharmacopeia method and whose quality exceeds the Eurofins 100% API reference standard (102% on the Certificate of Analysis). The product portfolio spans a >99% active ingredient plus oil dilutions (0.15%-5% in MCT and olive oil carriers) and powder dilutions (0.2%-1% in MCC and maltodextrin carriers), with a parallel consumer-facing brand, Vitaquinone®.

VitaSynth's technology platform is anchored by EU and USA patents on the second-generation synthesis process and by a comprehensive certification stack (FSSC 22000, GMP, HACCP from TÜV Rheinland; Kosher, Halal, Vegan, GMO Free; FDA inspection). The company moved commercial production in-house in 2017, opened a new manufacturing facility in 2024, and doubled production capacity in 2025, signaling a capacity-led scaling phase.

The business model is B2B enterprise field sales to brand managers and food supplement manufacturers, monetized through (i) ingredient sales of active K2 and pre-diluted oil and powder formulations, and (ii) a trademark and branding program offering 3-year fixed pricing, first-order discounts, and co-branding under the Pharmaquinone® identity. The company participates in flagship industry events (Vitafoods Geneva, SupplySide West Las Vegas) for customer acquisition and supports partners with technical documentation and a dedicated brand portal. VitaSynth was founded as a sister company to EuroPharma Alliance, which distributes complementary products in Central East Europe, and the company has received EU funds to support facility expansion.

Name

VitaSynth

Legal name

VITASYNTH sp. z o.o.

Website

https://vitasynth.eu

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

VitaSynth is a privately held Polish manufacturer of pharmaceutical-grade vitamin K2 MK-7 (Pharmaquinone®), selling patented single-peak ingredients and oil/powder dilutions via B2B enterprise sales to brand managers and food supplement manufacturers globally.

Ownership category

akta.pro rank

Product category

Vitamin K2 MK-7 nutraceutical ingredients

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Vitamins (A, B-Complex, C, D, E, K; Premixes) (AFAJAKAA)

Keywords

• Vitamin K2 manufacturing
• MK-7 active ingredients
• Nutraceutical raw materials
• Food fortification ingredients
• Dietary supplement manufacturing

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Vitamin K2 Ingredient Sales: Sale of vitamin K2 active ingredients and dilutions (oils and powders) to food supplement and pharmaceutical manufacturers for use in consumer products.
2. Trademark and Branding Program: Trademark agreements with 3-year fixed pricing that allow partners to use Pharmaquinone branding on their products, with special discounts on first orders.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

VitaSynth manufactures and sells pharmaceutical-grade vitamin K2 MK-7 active ingredients and pre-blended dilutions (oils and powders) under the Pharmaquinone® brand to food supplement and fortified-food manufacturers, complemented by a trademark and branding licensing program for partners. It also maintains the Vitaquinone® consumer-facing supplement brand. Production is performed at the company's own European manufacturing site using patented synthesis and purification processes.

Product overview

VitaSynth is a pharmaceutical-grade vitamin K2 manufacturer producing Pharmaquinone®, a premium line of vitamin K2 MK-7 ingredients and the consumer brand Vitaquinone®. The product portfolio centers on the patented "single-peak" Pharmaquinone® Active Ingredient (>99% purity), supported by a comprehensive range of oil dilutions (0.15%-5% in MCT and olive oil carriers) and powder dilutions (0.2%-1% in MCC and maltodextrin carriers). These formulations serve as food ingredients for brand managers and supplement manufacturers, while Vitaquinone® targets end consumers directly.

Differentiator

Problem solved

Functional benefit

Brands

• Pharmaquinone: Premium vitamin K2 MK-7 ingredient brand featuring the only 'single peak' vitamin K2 on the market, produced through patented manufacturing and purification processes. Product range includes >99% active ingredient, oil dilutions (0.15%-5% MCT Oil, 0.45% Olive Oil), and powder dilutions (0.2%-1% MCC Powder, 0.2% Maltodextrin Powder).
• Vitaquinone

Products and services

• Pharmaquinone® Active Ingredient (>99% MK-7) A >99% purity vitamin K2 as MK-7 active ingredient for use by food supplement and pharmaceutical manufacturers, produced using VitaSynth's patented "single-peak" manufacturing and purification process. Free of the cis isomer per the US Pharmacopeia method; the purest vitamin K2 available on the market.
• Pharmaquinone® 0.15% MCT Oil Oil dilution of vitamin K2 MK-7 in an MCT (medium-chain triglyceride) carrier at 0.15% concentration, designed for food fortification applications by supplement manufacturers.
• Pharmaquinone® 0.45% Olive Oil Oil dilution of vitamin K2 MK-7 in an olive oil carrier at 0.45% concentration, intended for food fortification applications by supplement manufacturers.
• Pharmaquinone® 1% MCT Oil Oil dilution of vitamin K2 MK-7 in an MCT (medium-chain triglyceride) carrier at 1% concentration, for food fortification applications by supplement manufacturers.
• Pharmaquinone® 5% MCT Oil Higher-concentration oil dilution of vitamin K2 MK-7 in an MCT (medium-chain triglyceride) carrier at 5%, for food fortification applications by supplement manufacturers.
• Pharmaquinone® 0.2% MCC Powder Powder dilution of vitamin K2 MK-7 in an MCC (microcrystalline cellulose) carrier at 0.2% concentration, for food fortification applications by supplement manufacturers.
• Pharmaquinone® 0.2% Maltodextrin Powder Powder dilution of vitamin K2 MK-7 in a maltodextrin carrier at 0.2% concentration, for food fortification applications by supplement manufacturers.
• Pharmaquinone® 0.25% MCC Powder Powder dilution of vitamin K2 MK-7 in an MCC (microcrystalline cellulose) carrier at 0.25% concentration, for food fortification applications by supplement manufacturers.
• Pharmaquinone® 1% MCC Powder Powder dilution of vitamin K2 MK-7 in an MCC (microcrystalline cellulose) carrier at 1% concentration, for food fortification applications by supplement manufacturers.
• Vitaquinone® Consumer Brand Consumer-facing brand of vitamin K2 MK-7 dietary supplements under the VitaSynth ecosystem, sold directly to end consumers via vitaquinone.eu.

Quantifiable outcome

• Quality exceeds official reference standard - 102% CoA vs Eurofins 100% API

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered major and core.

• Kappa Bioscience ASmajorStrategic or Co-development Partner · 1 January 2008Formerly Syntavit AS. MK-7 synthesis discussions began at SupplySide West, Las Vegas in 2008 between EuroPharma Alliance and Syntavit AS (future Kappa Bioscience AS). This partnership contributed to the development of vitamin K2 synthesis capabilities.
• EuroPharma AlliancecoreChannel Partner/ Reseller/ Distributor · 1 January 2007EuroPharma Alliance is a sister company to VitaSynth and became the sole distributor of Nattopharma in Central East Europe starting in 2007. VitaSynth was incorporated as a sister company to EuroPharma Alliance in 2009.
• Nattopharma ASAmajorStrategic or Co-development Partner · 1 January 2006Initial partnership began in 2006 with vitamin K2 introductory meetings at Vitafoods Geneva. In 2007, EuroPharma Alliance became sole distributor of Nattopharma in Central East Europe. In 2013, VitaSynth sold the first generation synthesis patent to Nattopharma ASA while retaining manufacturing rights. This represents a long-standing strategic relationship in the vitamin K2 space.

Scale indicators4 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• dsm-firmenich: Global ingredients and nutrition major with a broad vitamin portfolio (including K vitamins) and large-scale GMP/FSSC-certified production. Competes with VitaSynth for large supplement and food fortification accounts where customers want single-source multi-vitamin procurement.
• Lonza Group: Major CDMO and ingredient manufacturer with nutritional and microbial fermentation capabilities. Competes for K2 and broader supplement/functional ingredient contracts where customers want an alternative to dedicated single-molecule suppliers like VitaSynth.
• BASF: One of the world's largest nutritional ingredient producers, supplying vitamins and premixes to food, supplement and pharma customers. Overlaps with VitaSynth in K2 ingredient supply and competes on scale, regulatory documentation and global distribution.
• ADM Nutrition: Global agricultural processor with a sizable nutrition ingredient business, including vitamins and functional ingredients. Serves the same food supplement and food fortification customers VitaSynth targets, often as a multi-ingredient supplier.
• Glanbia Nutritionals: Supplier of nutritional premixes, proteins and ingredient systems to supplement and functional food brands. Competes with VitaSynth for B2B ingredient slots in formulated products and offers alternative or supplementary K2 sourcing options to the same end customers.
• Balchem Corporation: Parent company of Kappa Bioscience and a broader human nutrition/health ingredient platform. Competes with VitaSynth at the parent level across K2 ingredients, encapsulation technology and co-branded supply programs for supplement brands.

Direct peers

• Kappa Bioscience: Acquired the first-generation vitamin K2 MK-7 synthesis patent from VitaSynth in 2013 (via Nattopharma ASA) and is now the largest branded MK-7 supplier under Balchem. Directly competes with VitaSynth's Pharmaquinone on purity claims, GMP manufacturing, and B2B supplement customers worldwide.
• Gnosis by Lesaffre: Life sciences arm of Lesaffre producing natto-derived vitamin K2 as MK-7 for nutraceutical and food fortification markets. Overlaps directly with VitaSynth's target customers (food supplement manufacturers and brand managers) and competes on K2 ingredient quality and certifications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/vitasynth-sp-z-o-o

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VitaSynth